Quince Therapeutics’ (QNCX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report report published on Thursday,Benzinga reports. The firm currently has a $12.00 price target on the stock.

Several other equities research analysts have also recently issued reports on the company. Brookline Capital Management initiated coverage on Quince Therapeutics in a report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 target price on the stock. Rodman & Renshaw initiated coverage on Quince Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 target price on the stock. EF Hutton Acquisition Co. I raised Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. RODMAN&RENSHAW raised Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 29th. Finally, Maxim Group began coverage on Quince Therapeutics in a research report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price target for the company. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Quince Therapeutics has a consensus rating of “Buy” and a consensus target price of $9.50.

Quince Therapeutics Trading Up 3.7 %

Shares of QNCX stock opened at $1.95 on Thursday. Quince Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The business has a 50-day moving average of $1.80 and a 200 day moving average of $1.11. The stock has a market capitalization of $85.80 million, a PE ratio of -1.57 and a beta of 0.74.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC raised its holdings in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the period. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.